J Hematol Oncol: KMT2 family gene mutations can predict cancer patients' response to immune checkpoint therapy

Immune checkpoint therapy (ICT) can produce long-lasting anti-tumor responses in various cancer types, but not all cancer patients respond to ICT therapy.

More and more evidences show that there is a link between epigenetic regulation and anti- tumor immunity , and there is a lack of clinical data on the link between genomic changes in genes related to dysregulation of transcription and the clinical efficacy of ICT.

The histone-lysine N-methyltransferase 2 (KMT2) family of proteins methylate the lysine 4 at the tail of histone H3 in the important regulatory region of the genome, thereby regulating chromatin structure and DNA Accessibility to deliver key functions is related to the occurrence, mutagenesis and immune tolerance of a variety of cancers, indicating that KMT2 may be related to the prognosis of immune checkpoint therapy.

Researchers speculate that genomic mutations in the KMT2 family may be used as predictors of the efficacy of immunotherapy.

The overall survival risk ratio of cancer patients with mutations in the KMT2 family gene compared to wild-type patients

Through comprehensive cancer genome analysis of baseline tumor tissues in multiple patient cohorts receiving immunotherapy, the researchers found that KMT2 family gene mutations were significantly associated with better ICT treatment response in multiple patient cohorts.

KMT2 family gene mutations are significantly enriched in patients who respond to ICT therapy

Subsequently, the researchers further collected all independent ICT treatment data sets, a total of 418 patients.

Original source:

Zhang Peng,Huang Yixuan, org/10.